Ovid Therapeutics Inc. Common Stock

OVID Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of OVID by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
OVID Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
OVID Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
OVID Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in OVID holdings by institutional investors

Insider Trading

Quarterly net insider trading by OVID's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

OVID Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

OVID Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
OVID Income Statement
OVID Balance Sheet
OVID Cash Flow
U.S. Patents

New OVID patent grants

  • Patent Title: Methods of treating developmental disorders with gaboxadol Nov. 11, 2025
  • Patent Title: Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders Apr. 29, 2025
  • Patent Title: Methods and compositions for treatment of epileptic disorders Nov. 19, 2024
  • Patent Title: Methods and compositions for treatment of epileptic disorders Oct. 08, 2024
  • Patent Title: Methods and compositions for treatment of epileptic disorders Mar. 05, 2024
  • Patent Title: Methods of treating seizure disorders and prader-willi syndrome Mar. 05, 2024
  • Patent Title: Methods and compositions for treatment of epileptic disorders Feb. 20, 2024
  • Patent Title: Methods and compositions for treatment of epileptic disorders Nov. 07, 2023
  • Patent Title: Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction Oct. 03, 2023
  • Patent Title: Use of mir101 or mir128 in the treatment of seizure disorders Sep. 19, 2023
  • Patent Title: Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder Jul. 04, 2023
  • Patent Title: Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders May. 30, 2023
  • Patent Title: Methods and compositions for treatment of epileptic disorders Jul. 26, 2022
  • Patent Title: Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Jun. 21, 2022
  • Patent Title: Use of gaboxadol in the treatment of diabetes and related conditions Apr. 05, 2022
  • Patent Title: Methods for treating aggression associated with alzheimer's disease Mar. 22, 2022
  • Patent Title: Use of mir-92a or mir-145 in the treatment of angelman syndrome Sep. 28, 2021
  • Patent Title: Methods of treating developmental disorders with gaboxadol Aug. 24, 2021
  • Patent Title: Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering Aug. 17, 2021
  • Patent Title: Methods of treating developmental disorders and/or seizure disorders with etifoxine Feb. 23, 2021
  • Patent Title: Use of mir101 or mir128 in the treatment of seizure disorders Dec. 22, 2020
  • Patent Title: Use of mir101 or mir128 in the treatment of seizure disorders Nov. 17, 2020
  • Patent Title: Use of gaboxadol in the treatment of diabetes and related conditions Oct. 27, 2020
  • Patent Title: Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders Oct. 27, 2020
  • Patent Title: Methods and compositions for treatment of epileptic disorders Oct. 13, 2020
  • Patent Title: Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering Sep. 08, 2020
  • Patent Title: Methods of treating developmental encephalopathies Sep. 08, 2020
  • Patent Title: Methods of treating developmental syndromes with pde10a inhibitors Aug. 11, 2020
  • Patent Title: Use of mir-92a or mir-145 in the treatment of angelman syndrome Jul. 07, 2020
  • Patent Title: Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction May. 19, 2020
  • Patent Title: Methods of treating behavioral syndromes using pipradrol Dec. 03, 2019
  • Patent Title: Methods of treating developmental disorders with biguanides Oct. 01, 2019
  • Patent Title: Methods of treating developmental disorders and/or seizure disorders with etifoxine Sep. 24, 2019
  • Patent Title: Methods and compositions for treatment of epileptic disorders Jul. 30, 2019
  • Patent Title: Methods of treating seizure disorders Apr. 23, 2019
  • Patent Title: Methods of treating prader-willi syndrome Feb. 05, 2019
  • Patent Title: Use of gaboxadol in the treatment of tinnitus Jan. 29, 2019
  • Patent Title: Methods of treating developmental disorders with biguanides Nov. 13, 2018
  • Patent Title: Methods of sedation during critical care treatment Oct. 30, 2018
  • Patent Title: Methods of treating developmental disorders using pipradrol Mar. 13, 2018
  • Patent Title: Methods of treating behavioral syndromes using pipradrol Nov. 28, 2017
  • Patent Title: Methods of increasing tonic inhibition and treating secondary insomnia Oct. 31, 2017
  • Patent Title: Methods of treatment rett syndrome Aug. 29, 2017
  • Patent Title: Methods of sedation during critical care treatment Aug. 01, 2017
  • Patent Title: Methods of treating dravet syndrome Jun. 20, 2017
  • Patent Title: Methods of treating prader-willi syndrome Apr. 04, 2017
  • Patent Title: Methods of increasing tonic inhibition and treating fragile x syndrome and angelman syndrome Sep. 20, 2016
  • Patent Title: Methods of sedation during critical care treatment Jul. 26, 2016
  • Patent Title: Methods of treating developmental disorders using pipradrol May. 31, 2016
  • Patent Title: Methods of increasing tonic inhibition and treating secondary insomnia May. 17, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to OVID from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
OVID News

Recent insights relating to OVID

CNBC Recommendations

Recent picks made for OVID stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OVID

OVID Analyst Ratings

OVID Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
OVID Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $OVID stock a Buy, Sell, or Hold?

  • What is the price target for $OVID stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

OVID Top Shareholders
Shareholder
Shares Held
OVID Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $OVID stock?

  • Who owns the most shares of $OVID stock?

  • What funds own $OVID stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

OVID Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view OVID Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About OVID

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

  • Address New York, NY
  • Market Cap 99.7 million
  • Employees 23
  • Industrial Classification Pharmaceutical Preparations
Back To Top